TheEdgeResearch
Home / Stocks / BDSI

BioDelivery Sciences International, Inc. (BDSI)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$5.59 ▼ -0.09%
Market Cap
$577.1M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.00
52-Wk Range
2.5-5.62
CEO
Herm Cukier
Country
US
Currency
USD

BioDelivery Sciences International, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Raleigh, NC, US. The stock last traded at $5.59, down 0.09% on the session, giving a market capitalisation of $577.1M. On trailing twelve-month figures it carries a trailing P/E of 6.82, a net margin of 50.9%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
6.82
Price / Sales
3.46
Price / Book
3.07
EV / EBITDA
11.71
Gross margin
86.0%
Operating margin
22.3%
Net margin
50.9%
Return on equity
—
Debt / equity
0.31
Current ratio
2.45
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
200
IPO date
2002-07-25
Headquarters
Raleigh, NC, US
About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (BDSI) is a specialized pharmaceutical firm dedicated to the advancement and commercialization of therapeutic products designed for long-term health conditions, serving markets both within the United States and internationally. The company's product offerings leverage its proprietary BioErodible MucoAdhesive drug delivery system—a slender, dissolving polymer film intended for application to the inner cheek—in addition to other drug administration methodologies. Its portfolio includes several key products: BELBUCA, a buprenorphine buccal film, is utilized for the ongoing management of persistent pain. Symproic functions as a peripherally acting mu-opioid receptor antagonist, specifically addressing opioid-induced constipation in adult patients suffering from chronic non-cancer pain. This also covers individuals whose chronic pain is a result of prior cancer or its treatment, provided they do not require frequent increases in opioid dosage. ELYXYB, an oral solution containing celecoxib, provides treatment for adult migraines, irrespective of the presence of an aura. ONSOLIS, a soluble fentanyl film administered buccally, is intended for the management of sudden, severe "breakthrough" pain experienced by cancer patients. Founded in 1997, BioDelivery Sciences International, Inc. is headquartered in Raleigh, North Carolina. As of March 18, 2022, the company operates as a subsidiary of Collegium Pharmaceutical, Inc.

Comparable companies

BioDelivery Sciences International, Inc. is most often compared with the following Healthcare names:

ACCDALIMAPENEXAIGRALVIVVDRGLSSAGESHCRSVA
More research on BDSI
BDSI technical analysis BDSI TheEdge Score Compare against peers
Open full interactive analysis & DCF →